Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric ( mouse/ human) |
Target | staphylococcal lipoteichoic acid |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6462H9996N1728O2028S54 |
Molar mass | 146072.36 g·mol−1 |
(what is this?) (verify) |
Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010 [update], it is undergoing Phase II/III clinical trials. [1] [2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric ( mouse/ human) |
Target | staphylococcal lipoteichoic acid |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6462H9996N1728O2028S54 |
Molar mass | 146072.36 g·mol−1 |
(what is this?) (verify) |
Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010 [update], it is undergoing Phase II/III clinical trials. [1] [2]